RS50622B - Tretman limfoma t-ćelija primenom 10-propargil-10-diazaaminopterina - Google Patents

Tretman limfoma t-ćelija primenom 10-propargil-10-diazaaminopterina

Info

Publication number
RS50622B
RS50622B RSP-2008/0470A RSP20080470A RS50622B RS 50622 B RS50622 B RS 50622B RS P20080470 A RSP20080470 A RS P20080470A RS 50622 B RS50622 B RS 50622B
Authority
RS
Serbia
Prior art keywords
pdx
cell lymphoma
propargyl
treatment
lymphoma
Prior art date
Application number
RSP-2008/0470A
Other languages
English (en)
Serbian (sr)
Inventor
Owen A. O'connor
Francis Sirotnak
Original Assignee
Sloan-Kettering Institute For Cancer Research
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=34971703&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=RS50622(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Sloan-Kettering Institute For Cancer Research filed Critical Sloan-Kettering Institute For Cancer Research
Publication of RS50622B publication Critical patent/RS50622B/sr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/525—Isoalloxazines, e.g. riboflavins, vitamin B2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
RSP-2008/0470A 2004-05-30 2005-05-31 Tretman limfoma t-ćelija primenom 10-propargil-10-diazaaminopterina RS50622B (sr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US52159304P 2004-05-30 2004-05-30
PCT/US2005/019169 WO2005117891A1 (en) 2004-05-30 2005-05-31 Treatment of t-cell lymphoma using 10-propargyl-10-deazaaminopterin

Publications (1)

Publication Number Publication Date
RS50622B true RS50622B (sr) 2010-06-30

Family

ID=34971703

Family Applications (1)

Application Number Title Priority Date Filing Date
RSP-2008/0470A RS50622B (sr) 2004-05-30 2005-05-31 Tretman limfoma t-ćelija primenom 10-propargil-10-diazaaminopterina

Country Status (23)

Country Link
US (4) US7939530B2 (https=)
EP (1) EP1750716B1 (https=)
JP (1) JP5005532B2 (https=)
KR (1) KR101189693B1 (https=)
CN (2) CN102824346B (https=)
AT (1) ATE405272T1 (https=)
AU (1) AU2005249516B2 (https=)
BR (1) BRPI0510895A (https=)
CA (1) CA2565968C (https=)
DE (1) DE602005009176D1 (https=)
DK (1) DK1750716T3 (https=)
ES (1) ES2313365T3 (https=)
HR (1) HRP20080569T3 (https=)
ME (1) ME01087B (https=)
MX (1) MXPA06013559A (https=)
NO (1) NO337276B1 (https=)
NZ (2) NZ576849A (https=)
PL (1) PL1750716T3 (https=)
PT (1) PT1750716E (https=)
RS (1) RS50622B (https=)
SI (1) SI1750716T1 (https=)
WO (2) WO2005117891A1 (https=)
ZA (1) ZA200609266B (https=)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6835750B1 (en) 2000-05-01 2004-12-28 Accera, Inc. Use of medium chain triglycerides for the treatment and prevention of alzheimer's disease and other diseases resulting from reduced neuronal metabolism II
US8263354B2 (en) * 2004-05-30 2012-09-11 Sloan-Kettering Institute For Cancer Research Methods for assessing cancer for increased sensitivity to 10-propargyl-10-deazaaminopterin
US20080188479A1 (en) * 2004-05-30 2008-08-07 Sloan-Kettering Institute For Cancer Research Methods to Treat Cancer with 10-propargyl-10-deazaaminopterin and Methods for Assessing Cancer for Increased Sensitivity to 10-propargyl-10-deazaaminopterin
CA2565968C (en) 2004-05-30 2013-01-08 Sloan-Kettering Institute For Cancer Research Treatment of t-cell lymphoma using 10-propargyl-10-deazaaminopterin
KR101335021B1 (ko) 2007-07-31 2013-12-12 액세라인크 게놈 테스트의 용도 및 인지 기능 저하 치료용 케톤성 화합물
US20100248249A1 (en) * 2007-08-17 2010-09-30 Allos Therapeutics, Inc. Methods for Assessing Cancer for Increased Sensitivity to 10-Propargyl-10-Deazaaminopterin by Assessing Egfr Levels
US9901578B2 (en) 2007-08-17 2018-02-27 Allos Therapeutics, Inc. Combination of 10-propargyl-10-deazaaminopterin and erlotinib for the treatment of non-small cell lung cancer
WO2009026234A1 (en) * 2007-08-17 2009-02-26 Allos Therapeutics, Inc. Combination of 10-propargyl-10-deazaaminopterin and erlotinib for the treatment of non-small cell lung cancer
US9125881B2 (en) 2008-07-03 2015-09-08 Accera, Inc. Monoglyceride of acetoacetate and derivatives for the treatment of neurological disorders
WO2010022277A2 (en) * 2008-08-20 2010-02-25 O'connor Owen A Combination of 10-propargyl-10-deazaaminopterin and bortezomib for the treatment of cancers
US20110190305A1 (en) 2010-02-02 2011-08-04 Allos Therapeutics, Inc. Optically Pure Diastereomers of 10-Propargyl-10-Deazaaminopterin and Methods of Using Same
EP2575466B1 (en) * 2010-06-02 2015-04-08 Allos Therapeutics, Inc. Methods for treating methotrexate-resistant disorders with 10-propargyl-10-deazaaminopterin
US20130178441A1 (en) * 2010-08-10 2013-07-11 Allos Therapeutics, Inc. Methods for Extending Progression-Free Survival using 10-Propargyl-10-Deazaaminopterin
WO2013164856A1 (en) 2012-05-04 2013-11-07 Avra Laboratories Private Limited A process for preparing intermediates of 10-propargyl-10-deazaaminopterin (pralatrexate) synthesis and the intermediates thereof
CN103274943B (zh) * 2013-05-24 2015-01-21 苏州明锐医药科技有限公司 4-[1-(2-丙炔基)-3,4-二氧代正丁基]苯甲酸酯及其制备方法
WO2016205203A1 (en) 2015-06-16 2016-12-22 Spectrum Pharmaceuticals, Inc. Combination therapy using belinostat and pralatrexate to treat lymphoma

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4393064A (en) * 1976-03-05 1983-07-12 Sri International Process and composition for treatment of leukemia and process for preparing the same
US4652533A (en) * 1983-04-28 1987-03-24 Pandex Laboratories, Inc. Method of solid phase immunoassay incorporating a luminescent label
US4843155A (en) * 1987-11-19 1989-06-27 Piotr Chomczynski Product and process for isolating RNA
DE69133095T2 (de) * 1990-11-20 2003-03-27 Dade Behring Marburg Gmbh Cyclosporin-Immunoassay
US5354751A (en) * 1992-03-03 1994-10-11 Sri International Heteroaroyl 10-deazaamino-pterine compounds and use for rheumatoid arthritis
US5981592A (en) * 1995-03-13 1999-11-09 Loma Linda University Medical Center Method and composition for treating cystic fibrosis
US6323205B1 (en) * 1996-07-17 2001-11-27 Sloan-Kettering Institute For Cancer Research Combinations of 10-propargyl-10-deazaaminopterin and taxols and methods of using same in the treatment of tumors
PT944389E (pt) * 1996-07-17 2008-12-03 Sloan Kettering Inst Cancer Composições purificadas de 10-propargil-10-desaza-aminopterina e métodos para a sua utilização no tratamento de tumores
GB0128510D0 (en) * 2001-11-28 2002-01-23 Novartis Ag Organic compounds
CA2565968C (en) * 2004-05-30 2013-01-08 Sloan-Kettering Institute For Cancer Research Treatment of t-cell lymphoma using 10-propargyl-10-deazaaminopterin

Also Published As

Publication number Publication date
HRP20080569T3 (en) 2008-12-31
US8299078B2 (en) 2012-10-30
KR20110081327A (ko) 2011-07-13
WO2005117892A1 (en) 2005-12-15
CN102824346B (zh) 2015-04-22
BRPI0510895A (pt) 2007-11-27
CA2565968A1 (en) 2005-12-15
MXPA06013559A (es) 2007-04-24
US7939530B2 (en) 2011-05-10
AU2005249516A1 (en) 2005-12-15
EP1750716A1 (en) 2007-02-14
EP1750716B1 (en) 2008-08-20
KR101189693B1 (ko) 2012-10-10
CN102824346A (zh) 2012-12-19
WO2005117891A1 (en) 2005-12-15
SI1750716T1 (sl) 2009-06-30
PL1750716T3 (pl) 2009-01-30
US20080058280A1 (en) 2008-03-06
DK1750716T3 (da) 2008-12-08
JP5005532B2 (ja) 2012-08-22
NO337276B1 (no) 2016-02-29
US20100120777A1 (en) 2010-05-13
DE602005009176D1 (de) 2008-10-02
CA2565968C (en) 2013-01-08
AU2005249516B2 (en) 2010-11-18
NZ576849A (en) 2011-03-31
NZ551082A (en) 2009-06-26
ME01087B (me) 2012-12-20
ES2313365T3 (es) 2009-03-01
NO20065971L (no) 2006-12-22
US20050267117A1 (en) 2005-12-01
ZA200609266B (en) 2008-12-31
US20130053391A1 (en) 2013-02-28
CN1960734A (zh) 2007-05-09
ATE405272T1 (de) 2008-09-15
HK1177901A1 (en) 2013-08-30
PT1750716E (pt) 2008-11-04
US7622470B2 (en) 2009-11-24
JP2008501038A (ja) 2008-01-17

Similar Documents

Publication Publication Date Title
US20130053391A1 (en) Treatment of T-Cell Lymphoma using 10-propargyl-10-deazaaminopterin
US7893252B2 (en) Selectively depolymerized galactomannan polysaccharide
EP0944389B1 (en) Purified compositions of 10-propargyl-10-deazaaminopterin and methods of using same in the treatment of tumors
WO1998002163A9 (en) Purified compositions of 10-propargyl-10-deazaaminopterin and methods of using same in the treatment of tumors
US6323205B1 (en) Combinations of 10-propargyl-10-deazaaminopterin and taxols and methods of using same in the treatment of tumors
KR20220124739A (ko) 암의 치료를 위한 병용 요법
KR101189692B1 (ko) 10-프로파르질-10-데아자아미노프테린을 사용하는 ｔ-세포림프종의 치료
HK1177901B (en) Treatment of t-cell lymphoma using 10-propargyl-10-deazaaminopterin
WO2026030527A1 (en) Formulations for treating cancer
EP1891957A1 (en) Purified Compositions of 10-Propargyl-10-Deazaaminopterin and Methods of Using Same in the Treament of Tumors
CN114712353A (zh) 烟酰胺及含有其的组合物的制药用途
HK1110238A (en) Purified compositions of 10-propargyl-10-deazaaminopterin and methods of using same in the treament of tumors